1. Emerging Biopharmaceutical Markets to Witness Exponential
Growth
IMARC Group, one of the world‘s leading research and advisory firms, finds that the sales of
Biopharmaceuticals in Emerging markets will nearly triple its size from US$ 5.3 Billion in 2010 to
US$ 13.5 Billion in 2015
IMARC Group, one of the world‘s leading research and advisory firms, finds in its new report
“Global Biopharmaceutical Market Report & Forecast 2010-2015” that driven by a huge patient pool,
rapid economic growth and improving intellectual property rights, the sales of biopharmaceuticals in the seven
emerging markets - Russia, China, Turkey, Mexico, South Korea, India and Brazil will nearly triple from the
current US$ 5.3 Billion to more than US$ 13.6 billion by 2015.
As per the research findings, the treatment costs associated with biopharmaceuticals are extremely high and at
times can exceed hundreds of thousands of dollars a year. Since most of the healthcare costs in the emerging
markets are paid out-of-pocket, most patients cannot afford these treatments. However, the seven emerging
markets taken together account for more than three billion people, representing more than 45% of the total
Global population. So even if a small percentage of patients are able to afford these drugs, it still represents a
huge market potential. Moreover, the GDPs of emerging markets have witnessed strong growth during the last
few years, and this is likely to continue in the coming years as well. This is expected to create a huge middle
class that can afford innovative treatments.
The report also suggests that despite the huge opportunity, these markets will not be easy for western
manufacturers to penetrate. A major challenge for manufacturers entering these markets is the fact that
emerging markets are more complex and different from the developed markets as well as from each other. A
strategy that will work in Turkey will not work well in India or China. Manufacturers will have to devise
strategies, customized as per the requirements of the individual markets.
IMARC’s new report “Global Biopharmaceutical Market Report 2010-2015” gives a deep insight into the
global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to
understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure,
therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2015.
This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and
all those who are planning to foray into the global biopharmaceutical market in some form or the other.

2. Report Highlights:
 Biopharmaceuticals enjoy a higher approval success rate compared to traditional small molecule
drugs. They, however, require higher investments and take longer development times.
 Biopharmaceuticals are significantly more expensive than traditional medications, with the annual cost
of therapy of some biopharmaceuticals touching more than a hundred thousand dollars a year. The
cost of these drugs, however, is expected to be closely scrutinized by payers in the coming years.
 Recombinant Proteins represented the biggest biopharmaceutical class in 2009, accounting for more
than 65% of the total global biopharmaceutical sales. Growth in this class is expected to be low in most
of the developed markets as a result of biosimilar entry and increasing cost containment measures.
 Monoclonal Antibodies are expected to be the biggest drivers of the biopharmaceutical market in the
next five years. Driven by a rich late stage pipeline and a strong uptake from both developed and
emerging market, Monoclonal Antibodies are expected to be worth more than US$ 79 Billion by 2015.
 Imarc expects the top eight markets (US, Germany, Japan, France, Italy, Spain, UK and Canada) to
account for around 79% of the total global biopharmaceutical sales by 2015. This represents a decline
of 4% over their 2009 share.
 The market share of emerging markets (Brazil, Russia, India, China, Mexico, Turkey and South Korea)
is likely to increase from less than 5% in 2009 to more than 8% by 2015.
Countries Covered
Global, US, Germany, Japan, France, Italy, Spain, United Kingdom, Canada, Russia, China, Australia, Turkey,
Mexico, South Korea, India, Brazil, Argentina and Indonesia.
Classes Covered for Each Region/Country
Recombinant Proteins, Insulin, Erythropoietins, Interferons, Colony Stimulating Factors, Immunoglobulins,
Recombinant Blood Factors, Growth Hormones, Recombinant Enzymes, Interleukins, Growth Factors,
Monoclonal Antibodies and Purified Proteins.
Key Features
 Analysis of the key strengths, weaknesses, opportunities and threats faced by the global
biopharmaceutical market.
 Exhaustive in-depth individual analysis for eighteen major developed and emerging markets.
 2005 to 2009 trend analysis for the global and 18 selected biopharmaceutical markets.

3.  2005 to 2009 trend analysis for individual biopharmaceutical classes for the global and 18 selected
biopharmaceutical markets.
 2005 to 2009 trend analysis for the performance of top players for the global and 18 selected
biopharmaceutical markets.
Table of Contents
1. Market Definitions & Research Methodology
2. Analyst Briefing
3. Introduction to Biopharmaceuticals
4. Global Biopharmaceutical Market: Industry Analysis
4.1 Strengths
4.1.1 High Efficacy and Target Oriented Attack
4.1.2 Strong Potential to Achieve Blockbuster Status
4.1.3 Limited Generic Threat
4.1.4 Approval Success Rates are Higher than Small Molecule Drugs
4.2 Weaknesses
4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives
4.2.2 Second Line of Therapy
4.2.3 Huge Cost of Therapy
4.2.4 High Incidence of Unfavorable Side Effects
4.3 Opportunities
4.3.1 Diseases with High Unmet Needs
4.3.2 Expanding the Patient Pool by Approval into Additional Indications
4.3.3 Emerging Markets
4.3.4 Increasing New Approvals and a Strong Pipeline
4.4 Threats
4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
4.4.2 Biosimilars
4.4.3 Limited and Conditional Reimbursement
4.4.4 Uncertainties in the Economic Environment

4. 5. Global Biopharmaceutical Market: Industry Performance
5.1 Market Performance & Forecast
5.1.1 Current Performance (2005-2009)
5.1.2 Market Forecasts (2010-2015)
5.2 Market Segmentation by Region
5.2.1 Current Performance (2005-2009)
5.2.2 Market Forecasts (2010-2015)
5.3 Market Segmentation by Indication
5.4 Market Segmentation by Class
5.4.1 Recombinant Proteins
5.4.2 Monoclonal Antibodies
5.4.3 Purified Proteins
5.5 Competitive Landscape
5.5.1 Top Biopharmaceutical Players
5.5.2 Top Biopharmaceutical Drugs
6. North America
6.1 US
6.1.1 Market Performance (2005-2009)
6.1.2 Market Segmentation by Class
6.1.3 Performance of Top Players
6.1.4 Market Forecasts (2010-2015)
6.2 Canada
6.2.1 Market Performance (2005-2009)
6.2.2 Market Segmentation by Class
6.2.3 Performance of Top Players
6.2.4 Market Forecasts (2010-2015)
7. Latin America
7.1 Mexico
7.1.1 Market Performance (2005-2009)
7.1.2 Market Segmentation by Class

5. 7.1.3 Performance of Top Players
7.1.4 Market Forecasts (2010-2015)
7.2 Brazil
7.2.1 Market Performance (2005-2009)
7.2.2 Market Segmentation by Class
7.2.3 Performance of Top Players
7.2.4 Market Forecasts (2010-2015)
7.3 Argentina
7.3.1 Market Performance (2005-2009)
7.3.2 Market Segmentation by Class
7.3.3 Performance of Top Players
7.3.4 Market Forecasts (2010-2015)
8. Europe
8.1 Germany
8.1.1 Market Performance (2005-2009)
8.1.2 Market Segmentation by Class
8.1.3 Performance of Top Players
8.1.4 Market Forecasts (2010-2015)
8.2 France
8.2.1 Market Performance (2005-2009)
8.2.2 Market Segmentation by Class
8.2.3 Performance of Top Players
8.2.4 Market Forecasts (2010-2015)
8.3 Italy
8.3.1 Market Performance (2005-2009)
8.3.2 Market Segmentation by Class
8.3.3 Performance of Top Players
8.3.4 Market Forecasts (2010-2015)
8.4 Spain
8.4.1 Market Performance (2005-2009)

6. 8.4.2 Market Segmentation by Class
8.4.3 Performance of Top Players
8.4.4 Market Forecasts (2010-2015)
8.5 UK
8.5.1 Market Performance (2005-2009)
8.5.2 Market Segmentation by Class
8.5.3 Performance of Top Players
8.5.4 Market Forecasts (2010-2015)
8.6 Russia
8.6.1 Market Performance (2005-2009)
8.6.2 Market Segmentation by Class
8.6.3 Performance of Top Players
8.6.4 Market Forecasts (2010-2015)
8.7 Turkey
8.7.1 Market Performance (2005-2009)
8.7.2 Market Segmentation by Class
8.7.3 Performance of Top Players
8.7.4 Market Forecasts (2010-2015)
9. Asia Pacific
9.1 Japan
9.1.1 Market Performance (2005-2009)
9.1.2 Market Segmentation by Class
9.1.3 Performance of Top Players
9.1.4 Market Forecasts (2010-2015)
9.2 China
9.2.1 Market Performance (2005-2009)
9.2.2 Market Segmentation by Class
9.2.3 Performance of Top Players
9.2.4 Market Forecasts (2010-2015)
9.3 Australia

7. 9.3.1 Market Performance (2005-2009)
9.3.2 Market Segmentation by Class
9.3.3 Performance of Top Players
9.3.4 Market Forecasts (2010-2015)
9.4 South Korea
9.4.1 Market Performance (2005-2009)
9.4.2 Market Segmentation by Class
9.4.3 Performance of Top Players
9.4.4 Market Forecasts (2010-2015)
9.5 India
9.5.1 Market Performance (2005-2009)
9.5.2 Market Segmentation by Class11
9.5.3 Performance of Top Players
9.5.4 Market Forecasts (2010-2015)
9.6 Indonesia
9.6.1 Market Performance (2005-2009)
9.6.2 Market Segmentation by Class
9.6.3 Performance of Top Players
9.6.4 Market Forecasts (2010-2015)
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-425-6531
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145
IMARC Group Europe, Middle East & Africa
Email:ema@imarcgroup.com
Phone: +44-702-409-7331
To know more please visit: http://www.imarcgroup.com/global-biopharmaceutical-market-report-
2010-2015/

8. Keywords
Biopharmaceuticals market, Global Biopharmaceuticals market, Pharmaceuticals market, Recombinant proteins
market, Monoclonal anti-bodies market, Purified Proteins market

9.  2010-2015 sales forecast for the global and 18 selected biopharmaceutical markets.